Question:
Obinutuzumab (Gazivaro)
Author: Natalia AbesadaAnswer:
Anti CD20. Consideré comme "biobetter" du Rituximab, car il est afucosylé --> ADCC plus important + CDC moins important+ augmentation effet apoptotique. Ind: Leucemie lymphoide chronique et lymphome folliculaire.
0 / 5 (0 ratings)
1 answer(s) in total
Author
Natalia Abesada